The speakers emphasize that symptom burden can alter sequencing priorities and prompt greater integration of supportive interventions alongside tumor directed therapy. Regular symptom assessment and ...

In an interview, Vincent Ma, MD, explores the clinical utility of circulating tumor DNA dynamics to assess early outcomes in ...

In this interview, Sagar Lonial, MD, discussed the EXCALIBER-RRMM trial design and the potential role of iberdomide in the ...

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...

MRD testing in lymphoma grows fast, but varying assays and limited guidelines leave clinicians guessing; trials and standards clarify care.

A key takeaway from the analysis was that baseline ctDNA levels alone were not significantly predictive or prognostic. The ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

Early-phase clinical trials involving PIM-1 kinase inhibitors look promising. In the evolving landscape of myelofibrosis (MF) ...

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance.

Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

Price transparency compliance is often “in-form” rather than “in-spirit,” with many machine-readable files failing to provide complete, accurate, and usable drug pricing data. Reform priorities ...